Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 As Monotherapy Or In Combination With Either Nivolumab Or Pembrolizumab In HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

NCT04044859 is registered in ClinicalTrials.gov with USWM CT, LLC as lead sponsor.

NCT NCT04044859
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04044859 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 As Monotherapy Or In Combination With Either Nivolumab Or Pembrolizumab In HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
Lead sponsor
USWM CT, LLC
Phase
Phase 1
Overall status
Active, not recruiting
Start date
August 20, 2019
Completion date
April 30, 2037
Enrollment
120 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer, esophageal cancer, esophagogastric junction (egj), gastric (stomach) cancer, head and neck cancer, melanoma, non-small cell lung (nsclc), ovarian cancer, urothelial cancer